Alka A Potdar1, Shishir Dube1, Takeo Naito1, Katherine Li2, Gregory Botwin1, Talin Haritunians1, Dalin Li1, David Casero1, Shaohong Yang1, Janine Bilsborough1, Jacqueline G Perrigoue2, Lee A Denson3, Mark Daly4, Stephan R Targan1, Phillip Fleshner1, Jonathan Braun1, Subra Kugathasan5, Thaddeus S Stappenbeck6, Dermot P B McGovern7. 1. F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California. 2. Janssen Research and Development, LLC, Spring House, Pennsylvania. 3. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of Cincinnati College of Medicine and the Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 4. Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts; Analytic and Translational Genetics Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 5. Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia; Children's Healthcare of Atlanta, Atlanta, Georgia. 6. Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio. 7. F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California. Electronic address: dermot.mcgovern@cshs.org.
Abstract
BACKGROUND AND AIMS: The host receptor for severe acute respiratory syndrome coronavirus 2, angiotensin-converting enzyme 2 (ACE2), is highly expressed in small bowel (SB). Our aim was to identify factors influencing intestinal ACE2 expression in Crohn's disease (CD), ulcerative colitis (UC), and non-inflammatory bowel disease (IBD) controls. METHODS: Using bulk RNA sequencing or microarray transcriptomics from tissue samples (4 SB and 2 colonic cohorts; n = 495; n = 387 UC; n = 94 non-IBD), we analyzed the relationship between ACE2 with demographics and disease activity and prognosis. We examined the outcome of anti-tumor necrosis factor and anti-interleukin-12/interleukin-23 treatment on SB and colonic ACE2 expression in 3 clinical trials. Univariate and multivariate regression models were fitted. RESULTS: ACE2 levels were consistently reduced in SB CD and elevated in colonic UC compared with non-IBD controls. Elevated SB ACE2 was also associated with demographic features (age and elevated body mass index) associated with poor coronavirus disease 2019 outcomes. Within CD, SB ACE2 was reduced in patients subsequently developing complicated disease. Within UC, colonic ACE2 was elevated in active disease and in patients subsequently requiring anti-tumor necrosis factor rescue therapy. SB and colonic ACE2 expression in active CD and UC were restored by anti-cytokine therapy, most notably in responders. CONCLUSIONS: Reduced SB but elevated colonic ACE2 levels in IBD are associated with inflammation and severe disease, but normalized after anti-cytokine therapy, suggesting compartmentalization of ACE2-related biology in SB and colonic inflammation. The restoration of ACE2 expression with anti-cytokine therapy might be important in the context of severe acute respiratory syndrome coronavirus 2 infection and potentially explain reports of reduced morbidity from coronavirus disease 2019 in IBD patients treated with anti-cytokines.
BACKGROUND AND AIMS: The host receptor for severe acute respiratory syndrome coronavirus 2, angiotensin-converting enzyme 2 (ACE2), is highly expressed in small bowel (SB). Our aim was to identify factors influencing intestinal ACE2 expression in Crohn's disease (CD), ulcerative colitis (UC), and non-inflammatory bowel disease (IBD) controls. METHODS: Using bulk RNA sequencing or microarray transcriptomics from tissue samples (4 SB and 2 colonic cohorts; n = 495; n = 387 UC; n = 94 non-IBD), we analyzed the relationship between ACE2 with demographics and disease activity and prognosis. We examined the outcome of anti-tumor necrosis factor and anti-interleukin-12/interleukin-23 treatment on SB and colonic ACE2 expression in 3 clinical trials. Univariate and multivariate regression models were fitted. RESULTS: ACE2 levels were consistently reduced in SB CD and elevated in colonic UC compared with non-IBD controls. Elevated SB ACE2 was also associated with demographic features (age and elevated body mass index) associated with poor coronavirus disease 2019 outcomes. Within CD, SB ACE2 was reduced in patients subsequently developing complicated disease. Within UC, colonic ACE2 was elevated in active disease and in patients subsequently requiring anti-tumor necrosis factor rescue therapy. SB and colonic ACE2 expression in active CD and UC were restored by anti-cytokine therapy, most notably in responders. CONCLUSIONS: Reduced SB but elevated colonic ACE2 levels in IBD are associated with inflammation and severe disease, but normalized after anti-cytokine therapy, suggesting compartmentalization of ACE2-related biology in SB and colonic inflammation. The restoration of ACE2 expression with anti-cytokine therapy might be important in the context of severe acute respiratory syndrome coronavirus 2 infection and potentially explain reports of reduced morbidity from coronavirus disease 2019 in IBD patients treated with anti-cytokines.
Authors: Amanda Ricciuto; Christopher A Lamb; Eric I Benchimol; Gareth J Walker; Nicholas A Kennedy; M Ellen Kuenzig; Gilaad G Kaplan; Michael D Kappelman; Ryan C Ungaro; Jean-Frederic Colombel; Erica J Brenner; Manasi Agrawal; Walter Reinisch; Anne M Griffiths; Shaji Sebastian Journal: J Crohns Colitis Date: 2022-05-10 Impact factor: 10.020
Authors: Boglárka Soós; Miklós Fagyas; Ágnes Horváth; Edit Végh; Anita Pusztai; Monika Czókolyová; Alexandra Csongrádi; Attila Hamar; Zsófia Pethő; Nóra Bodnár; György Kerekes; Katalin Hodosi; Éva Szekanecz; Szilvia Szamosi; Sándor Szántó; Gabriella Szűcs; Zoltán Papp; Zoltán Szekanecz Journal: Front Med (Lausanne) Date: 2022-01-27
Authors: Takahiko Toyonaga; Kenza C Araba; Meaghan M Kennedy; Benjamin P Keith; Elisabeth A Wolber; Caroline Beasley; Erin C Steinbach; Matthew R Schaner; Animesh Jain; Millie D Long; Edward L Barnes; Hans H Herfarth; Kim L Isaacs; Jonathan J Hansen; Muneera R Kapadia; José Gaston Guillem; Ajay S Gulati; Praveen Sethupathy; Terrence S Furey; Camille Ehre; Shehzad Z Sheikh Journal: Sci Rep Date: 2021-06-29 Impact factor: 4.379